Patients with chronic myeloid leukaemia (CML) can rely on a wide spectrum of therapeutic opportunities. Optimal use of these opportunities ensures an excellent clinical outcome for patients and opens the gate for treatment-free remission (TFR). To accomplish this, however, proper integration of clinical and laboratory monitoring of CML patients is fundamental. As such, molecular response (MR) monitoring of patients at defined time points has emerged as a critical success factor for optimal disease management. Deeper MRs are associated with improved long-term survival outcomes and, more importantly, they are considered a gateway to TFR. During an educational session at the 2015 annual EHA meeting, Dr Simona Soverini, MD, PhD (University of Bologna, Italy), gave a critical overview on both the importance of monitoring deep responses to TKIs in CML patients and innovative technologies allowing for sensitive BCR-ABL1 detection.
(BELG J HEMATOL 2015;6(3):82–4)